Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
2007

Antimalarial Effects of Bortezomib and ZL3B

publication Evidence: moderate

Author Information

Author(s): Reynolds Jennifer M, El Bissati Kamal, Brandenburg Jens, Günzl Arthur, Mamoun Choukri Ben

Primary Institution: University of Connecticut Health Center

Hypothesis

Can bortezomib and its analog ZL3B be effective against malaria-causing parasites?

Conclusion

Bortezomib and ZL3B are effective against both drug-sensitive and resistant strains of malaria parasites.

Supporting Evidence

  • Bortezomib and ZL3B block the development of malaria parasites before DNA synthesis.
  • Both compounds were effective against drug-resistant strains of P. falciparum.
  • The study suggests the need for large-scale screening of clinically approved drugs for antimalarial activity.

Takeaway

Bortezomib and ZL3B can help fight malaria by stopping the parasites from growing.

Methodology

The study tested bortezomib and ZL3B against four strains of P. falciparum to assess their effectiveness.

Digital Object Identifier (DOI)

10.1186/1472-6904-7-13

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication